CL2019003660A1 - Posologías para la administración de análogos de péptido de tipo glucagon-2 (glp-2). - Google Patents
Posologías para la administración de análogos de péptido de tipo glucagon-2 (glp-2).Info
- Publication number
- CL2019003660A1 CL2019003660A1 CL2019003660A CL2019003660A CL2019003660A1 CL 2019003660 A1 CL2019003660 A1 CL 2019003660A1 CL 2019003660 A CL2019003660 A CL 2019003660A CL 2019003660 A CL2019003660 A CL 2019003660A CL 2019003660 A1 CL2019003660 A1 CL 2019003660A1
- Authority
- CL
- Chile
- Prior art keywords
- glp
- dosages
- administration
- treatment
- glucagon
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 108060003199 Glucagon Proteins 0.000 abstract 2
- 210000000936 intestine Anatomy 0.000 abstract 2
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 229940121355 glucagon like peptide 2 (glp-2) analogues Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
SE DESVELAN POSOLOGÍAS PARA LA ADMINISTRACIÓN DE ANÁLOGOS DE PÉPTIDO DE GLUCAGÓN 2 (GLP-2) Y SU USO MÉDICO, POR EJEMPLO, EN EL TRATAMIENTO Y/O PREVENCIÓN DE TRASTORNOS RELACIONADOS CON EL ESTÓMAGO Y EL INTESTINO Y PARA MEJORAR LOS EFECTOS SECUNDARIOS DE QUIMIOTERAPIA Y RADIOTERAPIA. SE DESCRIBEN POSOLOGÍAS PARA LA ADMINISTRACIÓN DE ANÁLOGOS DE PÉPTIDO DE TIPO GLUCAGÓN 2 (GLP-2) PARA INDUCIR EL CRECIMIENTO LONGITUDINAL DE LOS INTESTINOS, POR EJEMPLO, PARA EL TRATAMIENTO DE PACIENTES CON SÍNDROME DE INTESTINO PEQUEÑO (SBS). SE DESCRIBEN TAMBIÉN LOS USOS MÉDICOS PARA AJUSTAR EL VOLUMEN DEL SOPORTE PARENTERAL (PS) PROPORCIONADOS A LOS SUJETOS QUE RECIBEN TRATAMIENTO CON ANÁLOGOS DE GLP-2 EN RESPUESTA AL TRATAMIENTO Y A LOS ALGORITMOS PARA DETERMINAR LOS CAMBIOS DE VOLUMEN PS.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1709643.9A GB201709643D0 (en) | 2017-06-16 | 2017-06-16 | Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues |
| GBGB1714203.5A GB201714203D0 (en) | 2017-09-05 | 2017-09-05 | Dosage regimes for the administration of Glucagon-Like Peptide-2(GLP-2)Analogues |
| GBGB1800873.0A GB201800873D0 (en) | 2018-01-19 | 2018-01-19 | Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003660A1 true CL2019003660A1 (es) | 2020-05-04 |
Family
ID=62748940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003660A CL2019003660A1 (es) | 2017-06-16 | 2019-12-13 | Posologías para la administración de análogos de péptido de tipo glucagon-2 (glp-2). |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20200000883A1 (es) |
| EP (3) | EP3881861B1 (es) |
| JP (2) | JP7200238B2 (es) |
| KR (2) | KR102754148B1 (es) |
| CN (2) | CN118526577A (es) |
| AU (2) | AU2018285580B2 (es) |
| BR (1) | BR112019026711A2 (es) |
| CA (1) | CA3066523A1 (es) |
| CL (1) | CL2019003660A1 (es) |
| CO (1) | CO2019014028A2 (es) |
| DK (2) | DK3881861T3 (es) |
| ES (2) | ES2989204T3 (es) |
| IL (2) | IL271245B2 (es) |
| MX (2) | MX2019015054A (es) |
| PE (1) | PE20200678A1 (es) |
| SG (1) | SG11201912161SA (es) |
| TW (1) | TWI791539B (es) |
| WO (1) | WO2018229252A1 (es) |
| ZA (2) | ZA201908355B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3881861B1 (en) | 2017-06-16 | 2024-07-31 | Zealand Pharma A/S | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues |
| EP4041722A4 (en) | 2019-10-07 | 2023-12-13 | Kallyope, Inc. | GPR119 AGONISTS |
| BR112022017039A2 (pt) | 2020-02-28 | 2022-11-16 | Kallyope Inc | Agonistas de gpr40 |
| EP4153589A4 (en) | 2020-05-19 | 2024-06-12 | Kallyope, Inc. | AMPK ACTIVATORS |
| CN111560061A (zh) * | 2020-05-26 | 2020-08-21 | 成都圣诺生物制药有限公司 | 一种Gelpaglutide的制备方法 |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
| KR20230121853A (ko) * | 2020-12-16 | 2023-08-21 | 질랜드 파마 에이/에스 | 신부전증 환자에서 glp-2 유사체의 용도 |
| EP4398872B1 (en) | 2021-09-10 | 2025-10-22 | Zealand Pharma A/S | Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues |
| CA3241692A1 (en) | 2021-12-23 | 2023-06-29 | Claes MELANDER | Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues |
| WO2023132609A1 (ko) * | 2022-01-05 | 2023-07-13 | 주식회사 휴온스랩 | 지속형 지방산-펩타이드 유도체 및 이의 용도 |
| AU2023225231A1 (en) * | 2022-02-24 | 2024-10-03 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of glucagon-like peptide-2 |
| IL319890A (en) * | 2022-09-30 | 2025-05-01 | Zealand Pharma As | Glucagon-like peptide-2 (GLP-2) analogs and their medical uses for the treatment of short bowel syndrome (SBS) |
| EP4654986A1 (en) | 2023-01-27 | 2025-12-03 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) |
| CN116478269A (zh) * | 2023-04-28 | 2023-07-25 | 成都奥达生物科技有限公司 | 一种长效替度鲁肽化合物 |
| WO2025141129A1 (en) | 2023-12-28 | 2025-07-03 | Zealand Pharma A/S | Formulations of glucagon-like-peptide 2 (glp-2) analogues and their uses |
| WO2025181330A1 (en) * | 2024-02-29 | 2025-09-04 | Vectivbio Ag | Dosage regimens for glucagon-like peptide 2 (glp-2) analogs |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2961045B2 (ja) | 1993-02-24 | 1999-10-12 | 日清製粉株式会社 | 腸管粘膜増強促進剤 |
| US6184208B1 (en) | 1994-06-29 | 2001-02-06 | Immunotech Developments Inc. | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide |
| US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| BR9707807A (pt) | 1996-03-01 | 1999-07-27 | Novo Nordisk As | Uso de uma composição farmacêutica composição farmacêutica processo de tratar doenças ou distúrbios associados com a regulação do apetite prejudicado e uso de um peptideo |
| US5912229A (en) | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
| BRPI9708566B8 (pt) | 1996-04-12 | 2022-01-18 | Ontario Inc 1149336 | análogo de glp-2 de mamífero, e, composição farmacêutica. |
| US5994500A (en) | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
| US20020025933A1 (en) | 1996-08-30 | 2002-02-28 | Knudsen Liselotte Bjerre | GLP-2 derivatives |
| EP0929567B1 (en) | 1996-09-09 | 2005-03-02 | Zealand Pharma A/S | Solid-phase peptide synthesis |
| US5952301A (en) | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
| CA2236519C (en) | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| US6051557A (en) | 1997-05-16 | 2000-04-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
| DE69819488T2 (de) | 1997-05-16 | 2004-08-26 | 1149336 Ontario Inc., Toronto | Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes |
| EP2433623A1 (en) | 1998-02-02 | 2012-03-28 | Trustees Of Tufts College | Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism |
| CA2321026A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| WO1999058144A1 (en) | 1998-05-11 | 1999-11-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| WO2001041779A2 (en) | 1999-12-08 | 2001-06-14 | 1149336 Ontario Inc. | Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| PT1326630E (pt) | 2000-09-18 | 2008-09-02 | Sanos Bioscience As | Utilização de péptidos glp-2 |
| WO2002066062A2 (en) | 2001-02-01 | 2002-08-29 | Drucker Daniel J | Enhancement of glp-2 activity |
| EP1360202B1 (en) | 2001-02-16 | 2008-05-21 | ConjuChem Biotechnologies Inc. | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
| US7144863B2 (en) | 2001-06-01 | 2006-12-05 | Eli Lilly And Company | GLP-1 formulations with protracted time action |
| WO2004035624A2 (en) | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
| DE60317822D1 (de) | 2002-10-29 | 2008-01-10 | Alza Corp | Stabilisierte feste polypeptidpartikel |
| EP2932981B1 (en) | 2003-09-19 | 2021-06-16 | Novo Nordisk A/S | Albumin-binding derivatives of GLP-1 |
| CN113304250A (zh) | 2003-11-20 | 2021-08-27 | 诺和诺德股份有限公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
| TW200536859A (en) | 2004-01-27 | 2005-11-16 | Nuvelo Inc | Gastrointestinal proliferative factor and uses thereof |
| WO2005082404A2 (en) | 2004-02-27 | 2005-09-09 | Novo Nordisk A/S | Glp-2 derivatives modified by lipophilic substituents |
| JP5197012B2 (ja) * | 2004-11-01 | 2013-05-15 | エヌピーエス ファーマシューティカルズ インコーポレイテッド | 大腸連続性を伴う短腸症候群患者の治療 |
| AU2006242998B2 (en) * | 2005-05-04 | 2012-03-22 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
| EP1922336B1 (en) | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| CN101331224A (zh) * | 2005-10-24 | 2008-12-24 | 森托科尔公司 | Glp-2模拟体、多肽、组合物、方法和用途 |
| US20090105341A1 (en) | 2005-12-24 | 2009-04-23 | Teagasc Dairy Products Research Centre | Process for the production of trans-10, cis 12 octadecadienoic acid |
| US20090028832A1 (en) | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| UA102506C2 (ru) * | 2006-11-08 | 2013-07-25 | Зиланд Фарма А/С | Селективные аналоги глюкагоноподобного пептида-2 (glp-2) |
| WO2008082656A1 (en) | 2006-12-29 | 2008-07-10 | Ipsen Pharma S.A.S. | Glp-1 pharmaceutical compositions |
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| GEP20135944B (en) | 2007-02-15 | 2013-10-25 | Indiana Unversity Research And Tech Corporation | Glucagon/glp-1 receptor co-agonists |
| TWI474832B (zh) | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | 胰高血糖素／ｇｌｐ-１受體共同激動劑 |
| WO2010070251A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| PE20120332A1 (es) | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
| CN102942626B (zh) | 2009-03-05 | 2015-11-04 | 江苏豪森医药集团有限公司 | 胰高血糖素样肽-2类似物及其制备方法和用途 |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| US20130053310A1 (en) | 2010-03-26 | 2013-02-28 | Novo Nordisk A/S | Novel glucagon analogues |
| JP2013533217A (ja) | 2010-05-17 | 2013-08-22 | セビックス・インコーポレイテッド | Ｐｅｇ化ｃ−ペプチド |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| MX2012014576A (es) | 2010-06-24 | 2013-02-21 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida. |
| CN102212127B (zh) | 2011-05-17 | 2015-02-04 | 上海景泽生物技术有限公司 | 胰高血糖素样肽-2聚乙二醇结合物及其制备方法和用途 |
| KR20230023059A (ko) | 2011-05-18 | 2023-02-16 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 제약 |
| ES2687651T3 (es) * | 2011-09-12 | 2018-10-26 | Amunix Operating Inc. | Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos |
| EA028929B1 (ru) | 2012-05-03 | 2018-01-31 | Зилэнд Фарма А/С | Аналоги глюкагоноподобного пептида-2 (glp-2) |
| JP6534927B2 (ja) | 2012-07-23 | 2019-06-26 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| US20160067311A1 (en) * | 2014-09-10 | 2016-03-10 | Helsinn Healthcare Sa | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea |
| ES2964713T3 (es) | 2014-10-23 | 2024-04-09 | Amgen Inc | Reducción de la viscosidad de formulaciones farmacéuticas |
| CN107257681A (zh) | 2014-12-23 | 2017-10-17 | 卡姆拉斯公司 | 控释配制品 |
| WO2016133863A1 (en) | 2015-02-17 | 2016-08-25 | Eli Lilly And Company | Nasal powder formulation for treatment of hypoglycemia |
| WO2017053822A1 (en) | 2015-09-23 | 2017-03-30 | Behavioral Recognition Systems, Inc. | Detected object tracker for a video analytics system |
| EP4591853A1 (en) | 2016-11-21 | 2025-07-30 | Amylyx Pharmaceuticals, Inc. | Buffered formulations of exendin (9-39) |
| JP6563614B1 (ja) | 2016-12-09 | 2019-08-21 | ジーランド・ファーマ・ア／エス | アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト |
| WO2018142363A1 (en) | 2017-02-06 | 2018-08-09 | Orbicular Pharmaceutical Technologies Private Limited | Ready to use compositions of glp-2 analogues through self-administrable devices |
| EP3881861B1 (en) | 2017-06-16 | 2024-07-31 | Zealand Pharma A/S | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues |
| GB201710822D0 (en) | 2017-07-05 | 2017-08-16 | Zealand Pharma As | Methods and medical uses relating to the treatment of hypoglycaemia |
| US20190275110A1 (en) | 2017-12-07 | 2019-09-12 | Adocia | Compositions in the form of an injectale aqueous solution comprising human glucagon and a co-polyamino acid |
| WO2020020904A1 (en) | 2018-07-23 | 2020-01-30 | Zealand Pharma A/S | Therapeutic uses of glp-2 agonists |
| EP3628683A1 (en) | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| US20200254065A1 (en) * | 2019-02-11 | 2020-08-13 | Opko Biologics Ltd. | Long-acting glp-2 analogs |
-
2018
- 2018-06-15 EP EP21150552.4A patent/EP3881861B1/en active Active
- 2018-06-15 DK DK21150552.4T patent/DK3881861T3/da active
- 2018-06-15 IL IL271245A patent/IL271245B2/en unknown
- 2018-06-15 JP JP2020519850A patent/JP7200238B2/ja active Active
- 2018-06-15 KR KR1020237006296A patent/KR102754148B1/ko active Active
- 2018-06-15 SG SG11201912161SA patent/SG11201912161SA/en unknown
- 2018-06-15 DK DK18734135.9T patent/DK3638291T3/da active
- 2018-06-15 ES ES21150552T patent/ES2989204T3/es active Active
- 2018-06-15 CN CN202410762243.2A patent/CN118526577A/zh active Pending
- 2018-06-15 MX MX2019015054A patent/MX2019015054A/es unknown
- 2018-06-15 EP EP18734135.9A patent/EP3638291B1/en active Active
- 2018-06-15 BR BR112019026711-5A patent/BR112019026711A2/pt unknown
- 2018-06-15 ES ES18734135T patent/ES2894629T3/es active Active
- 2018-06-15 CN CN201880053014.6A patent/CN111032072A/zh active Pending
- 2018-06-15 WO PCT/EP2018/065951 patent/WO2018229252A1/en not_active Ceased
- 2018-06-15 PE PE2019002548A patent/PE20200678A1/es unknown
- 2018-06-15 CA CA3066523A patent/CA3066523A1/en active Pending
- 2018-06-15 KR KR1020207001446A patent/KR102504200B1/ko active Active
- 2018-06-15 TW TW107120806A patent/TWI791539B/zh active
- 2018-06-15 IL IL299864A patent/IL299864B2/en unknown
- 2018-06-15 EP EP24182737.7A patent/EP4424362A3/en active Pending
- 2018-06-15 AU AU2018285580A patent/AU2018285580B2/en active Active
-
2019
- 2019-07-15 US US16/511,766 patent/US20200000883A1/en not_active Abandoned
- 2019-12-12 CO CONC2019/0014028A patent/CO2019014028A2/es unknown
- 2019-12-13 MX MX2023003828A patent/MX2023003828A/es unknown
- 2019-12-13 CL CL2019003660A patent/CL2019003660A1/es unknown
- 2019-12-13 ZA ZA2019/08355A patent/ZA201908355B/en unknown
-
2022
- 2022-12-20 JP JP2022203265A patent/JP7566859B2/ja active Active
-
2023
- 2023-10-27 US US18/496,636 patent/US12297251B1/en active Active
-
2024
- 2024-03-13 ZA ZA2024/02068A patent/ZA202402068B/en unknown
- 2024-04-16 AU AU2024202486A patent/AU2024202486B2/en active Active
- 2024-11-22 US US18/956,370 patent/US20250136657A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003660A1 (es) | Posologías para la administración de análogos de péptido de tipo glucagon-2 (glp-2). | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| MX2023010869A (es) | Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos. | |
| MX2021005561A (es) | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco. | |
| AR103246A1 (es) | Derivados de fgf21 y sus usos | |
| MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
| MX2013002207A (es) | Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13. | |
| CO2018006358A2 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| BR112018001761A2 (pt) | uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética | |
| CL2024001738A1 (es) | Vacunas peptídicas | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| AU2018326364A1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease | |
| CL2017002293A1 (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2 | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| AR116451A1 (es) | Administración oral de análogos del péptido glp-1 | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| CL2020000471A1 (es) | Regímenes de tratamiento. | |
| DOP2019000072A (es) | Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso | |
| CO2022014452A2 (es) | Formulaciones líquidas de análogos de glucagón | |
| MX2023005295A (es) | Tratamiento contra el cancer resistente a platino. | |
| AR112109A1 (es) | Regímenes de dosificación para la administración de análogos de glucagón-péptido-2 (glp-2) | |
| CO2022004947A2 (es) | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente | |
| PH12018500889A1 (en) | Pharmaceutical preparation for delivery of porous material to large intestine or lower part of small intestine | |
| AR108879A1 (es) | Dispositivo para la esterilización de bolsas flexibles mediante irradiación por haz de electrones y procedimiento de esterilización de las mismas | |
| MX2018011685A (es) | Proceso para formulaciones solidas de mesalazina. |